Renal cell carcinoma (RCC) is a kidney cancer in which immune signaling, metastatic behavior, and treatment response are active areas of study. A key mechanism highlighted here is STING promoter hypomethylation with increased STING expression in tumor tissue versus normal tissue, which was associated with immune cell infiltration and poor overall survival. RCC is also being explored in the context of oligoprogressive disease, where limited metastatic progression can occur, and in neoadjuvant therapy settings where no approved regimens currently exist outside clinical trials. Recent work also emphasizes immune checkpoint inhibitors, nanomedicine, and bioorthogonal fluorogenic probe-based approaches for immunotherapy and noninvasive response monitoring. Overall, the literature points to RCC as a disease with evolving biomarker-driven prognosis and translational imaging strategies, alongside emerging combination immunotherapy approaches.
Immune signaling and prognosis
- STING promoter hypomethylation and increased STING expression were observed in RCC tumor tissues compared with normal tissues, and this pattern was linked to poor overall survival. (PMID:41942521)
- STING expression and promoter methylation were associated with clinicopathological characteristics and immune cell infiltration in RCC. (PMID:41942521)
- A 2026 Scientific Reports study (PMID:41942521) specifically evaluated the prognostic significance and immune correlation of STING in RCC. (PMID:41942521)
Immunotherapy and treatment strategies
- Immune checkpoint inhibitor-based combinations demonstrated feasibility, safety, and pathologic responses in RCC. (PMID:41774881)
- RCC was highlighted as a disease area where neoadjuvant systemic therapy remains investigational, with no approved neoadjuvant regimens recommended outside clinical trials. (PMID:41774881)
- Nanomedicine-enabled immunotherapeutic strategies are being reviewed as a translational approach for urinary system tumors, including RCC. (PMID:41947122)
- A 2026 Journal of Nanobiotechnology review (PMID:41947122) discussed synergistic strategies and translational challenges for nanomedicine in RCC immunotherapy. (PMID:41947122)
Metastatic progression and response monitoring
- Some patients with RCC develop oligoprogressive disease, defined as limited metastatic progression, which has implications for clinical management. (PMID:41979231)
- A 2026 Expert Review of Anticancer Therapy article (PMID:41979231) focused on the clinical management of oligoprogressive RCC. (PMID:41979231)
- Bioorthogonal fluorogenic reporters were used for noninvasive imaging and urinalysis of immunotherapeutic response in RCC. (PMID:42028639)
- A 2026 Advanced Science study (PMID:42028639) evaluated these probes as a diagnostic tool for monitoring immunotherapy response in RCC. (PMID:42028639)